cash flow reconciliationreview2026-06-30
Operating, investing and financing flows differ from the reported change in cash by 12400000, beyond tolerance 4926000.00.
Revenue
$2.59B
Fiscal year ended 2026-06-30Operating income
$53.10M
Fiscal year ended 2026-06-30Free cash flow
$353.10M
Fiscal year ended 2026-06-30BIO-RAD LABORATORIES, INC. (BIO) reported revenue of $2.59B and net income of $222.40M for the fiscal year ended 2026-06-30. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from BIO-RAD LABORATORIES, INC.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Laboratory Analytical Instruments.
Income
| Metric | 2026-06-30 |
|---|---|
| Revenue | $2.59B |
| Cost of revenue | $1.25B |
| Gross profit | $1.34B |
| Operating income | $53.10M |
| Net income | $222.40M |
| Research & development | $265.70M |
| Weighted-average diluted shares | Unavailable |
| Pretax income | $350.40M |
| Income tax expense | $128.00M |
| Diluted EPS | Unavailable |
| Selling, general & administrative | $852.20M |
| General & administrative | Unavailable |
| Selling & marketing | Unavailable |
Balance
| Metric | 2026-06-30 |
|---|---|
| Cash & equivalents | $517.00M |
| Total assets | $10.25B |
| Current assets | $3.02B |
| Total liabilities | $3.08B |
| Current liabilities | $961.30M |
| Total equity incl. NCI | $7.17B |
| Temporary (mezzanine) equity | Unavailable |
| Inventory | $780.60M |
| Accounts receivable | $441.80M |
| Goodwill | $574.30M |
| Long-term debt | $803.00M |
| Accounts payable | $143.50M |
Cash flow
| Metric | 2026-06-30 |
|---|---|
| Operating cash flow | $492.60M |
| Capital expenditures | $139.50M |
| Investing cash flow | -$237.10M |
| Financing cash flow | -$120.80M |
| Net change in cash | $147.10M |
| Stock-based compensation | $60.30M |
| Common dividends paid | Unavailable |
| Common share repurchases | $132.70M |
| Depreciation & amortization | Unavailable |
Derived
| Metric | 2026-06-30 |
|---|---|
| Free cash flow | $353.10M |
| Gross margin | 51.9% |
| Operating margin | 2.1% |
| FCF margin | 13.6% |
| SBC / revenue | 2.3% |
| Current ratio | 3.14x |
| Revenue YoY growth | 1.4% |
| Net margin | 8.6% |
| R&D / revenue | 10.3% |
| CapEx / revenue | 5.4% |
| Long-term debt / equity | 0.11x |
| Effective tax rate | 36.5% |
Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open BIO in the interactive workspace to inspect any figure back to its filing.
Source filings
10-Q · Filed 2026-08-04View SEC filing
10-Q · Filed 2026-04-30View SEC filing
10-K · Filed 2026-02-13View SEC filing
10-Q · Filed 2025-10-29View SEC filing
10-Q · Filed 2025-07-31View SEC filing
10-Q · Filed 2025-05-01View SEC filing
Reconciliation checks needing review
1 period on this page do not reconcile under this site’s normalization. Read that as a limitation here before an observation about the company: the figures are the filer’s own, the filings linked above are authoritative, and a difference usually means the concepts this site selected do not match how this filer presents its statements. Nothing is adjusted to make a check pass.